CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Chiome Bioscience Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Chiome Bioscience Inc
12F,Smtm Fdsn Nshi-shnjk Bldg. No.6
3-12-1, Hon-machi
Phone: +81 363833561p:+81 363833561 SHIBUYA-KU, TKY  151-0071  Japan Ticker: 45834583

Business Summary
Chiome Bioscience Inc. is a company mainly engaged in the research and development of antibody drugs, and the provision of development support services. The Company operates in two business segments. The Drug Discovery segment is engaged in the research and development of specific antibodies based on new antigens and mechanisms and licensing to pharmaceutical companies. The Drug Discovery Support segment is engaged in development of lead antibodies for therapeutic drugs in collaborating with pharmaceutical companies in Japan and overseas.
(Source: F-4)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Representative Director ShigeruKobayashi 63 2/14/2017 1/1/2011
Chief Financial Officer, Manager of Business Planning Office, Director ArihikoBijohira 44 3/29/2017 1/1/2016
Chief Director of Development, Director ShoseTaoka 3/1/2023 3/1/2023
Independent Director MasamichiKoike 60 3/1/2023 3/1/2023
Independent Director HaruhisaKubota 73 3/1/2019 3/1/2019

General Information
Number of Employees: 51 (As of 12/31/2023)
Outstanding Shares: 55,714,451 (As of 3/29/2024)
Shareholders: 21,041
Stock Exchange: TYO


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024